Amgen Inc.

🇺🇸NASDAQ Global Select

Articles

57
Show Summary
Show Bulletpoints
Detailed View
Slightly Bullish +25

AMGEN ANNOUNCES RETIREMENT OF DAVID M. REESE, EXECUTIVE VICE PRESIDENT AND CHIEF TECHNOLOGY OFFICER

👴 David Reese retires as CTO effective June 30, 2026.

🤖 James Bradner succeeds Reese leading R&D, AI, and Data.

🧬 New leaders advance science-tech integration and global policy roles.

💼 Amgen continues broad pipeline focus on cancer and rare diseases.

🏆 Company retains top market index honors and innovation awards.

👴 Amgen announces the retirement of David M. Reese, Executive Vice President and Chief Technology Officer, effective June 30, 2026.

🔬 Reese joined Amgen in 2005 and previously served as Executive Vice President of Research and Development from 2018 to 2023.

💡 During his tenure, Reese led approvals of innovative medicines and biosimilars while advancing the company's pipeline and discovery research capabilities.

🤖 As inaugural Chief Technology Officer, Reese championed the early adoption of technology and artificial intelligence across Amgen's business operations.

🤝 CEO Robert A. Bradway praised Reese for recognizing the impact of biology-technology convergence and positioning Amgen for future patient care.

🚀 Effective June 1, 2026, James Bradner will become Executive Vice President of Research and Development, Artificial Intelligence and Data.

📊 Sean Bruich is set to serve as Senior Vice President, Chief Technology Officer, leveraging his expertise in global insights and AI organizations.

🏛️ Murdo Gordon will take on the role of Executive Vice President for Amgen Global Markets and Policy, including Medical and Commercial Operations.

🩺 Paul Burton will continue serving as Senior Vice President and Chief Medical Officer to reach clinicians with medicines in unmet need areas.

🧬 The organizational changes are designed to deepen the integration of science and technology across Amgen's ecosystem.

💼 Amgen continues to focus on a broad pipeline treating cancer, inflammatory conditions, rare diseases, heart disease, and obesity.

🏆 The company is recognized for innovation and workplace culture, including honors from Fast Company and Forbes.

📈 Amgen remains part of the Dow Jones Industrial Average and the Nasdaq-100 Index based on market capitalization.

🌐 This press release includes standard forward-looking statements regarding collaborations, financial metrics, and regulatory outcomes.

Bullish Signals
  • Amgen transitions to converge biology and technology leadership.
  • Capabilities position company for future convergent innovation.
  • James Bradner joins AI and R&D executive role.
  • Sean Bruich continues as CTO with global insights.
  • Paul Burton remains CMO championing breakthrough treatments.
  • Pipeline targets cancer, rare diseases, heart disease and obesity.
  • Amgen recognized for innovation by Fast Company and Forbes.
  • Stock in Dow Jones and Nasdaq-100 indices.
Risk Factors
  • David M. Reese retires as CTO on June 30, 2026.
  • Transition risks threaten Amgen's convergent innovation strategy before June 1, 2026.
  • Uncertainty remains regarding long-term technological continuity since his 2005 tenure.
Bullish Signals
  • The retirement of David M. Reese marks a strategic transition that emphasizes the integration of biology and technology at Amgen.
  • Robert A. Bradway noted that capabilities built under Reese's tenure position the company to advance 'convergent innovation' and better serve patients in the years ahead.
  • James Bradner is stepping into the new role of Executive Vice President, Research and Development, Artificial Intelligence and Data, bringing expertise at the intersection of biology and technology.
  • Sean Bruich will continue as Senior Vice President, Chief Technology Officer, building on a career leading global insights and AI organizations through pivotal moments of industry transformation.
  • Paul Burton, M.D., Ph.D., will remain Senior Vice President, Chief Medical Officer, championing medical breakthroughs in areas of unmet need from cardiovascular to rare diseases.
  • Amgen continues to advance a broad pipeline of medicines to treat cancer, inflammatory conditions, rare diseases, heart disease and obesity-related conditions.
  • Amgen has been consistently recognized for innovation and workplace culture with honors from Fast Company and Forbes.
  • As part of the Dow Jones Industrial Average and the Nasdaq-100 Index, Amgen remains at the cutting edge of innovation using technology and human genetic data.
Risk Factors
  • The retirement of David M. Reese as Executive Vice President and Chief Technology Officer effective June 30, 2026, signals a significant departure of leadership who had been pivotal in driving the early adoption of technology and artificial intelligence across the business.
  • This organizational change may introduce transition risks to Amgen's 'convergent innovation' strategy as new leaders assume responsibility for critical R&D and AI functions with limited time to implement immediate changes before June 1, 2026.
  • The announcement does not detail specific performance metrics or reasons for Reese's departure other than retirement, leaving uncertainty about the long-term continuity of the technological capabilities he built over his tenure since 2005.
Neutral +3

AMGEN ANNOUNCES RETIREMENT OF DAVID M. REESE, EXECUTIVE VICE PRESIDENT AND CHIEF TECHNOLOGY OFFICER - PR Newswire

👴 CTO David Reese retiring effective June 30, 2026 after 20-year tenure.

⚡ Organizational restructuring June 1, 2026 deepens biology and technology integration.

💊 Focus remains on cancer, inflammation, rare diseases, heart disease, and obesity.

👴 Amgen announced the retirement of David M. Reese, Executive Vice President and Chief Technology Officer, effective June 30, 2026.

💼 Dr. Reese joined Amgen in 2005 and previously served as executive vice president of Research and Development from 2018 to 2023.

🧬 During his tenure, he led approvals of innovative medicines and biosimilars while advancing the company's pipeline and discovery research capabilities.

🤖 As inaugural CTO, Reese championed early adoption of technology and artificial intelligence across Amgen's business, particularly in R&D.

🗣️ CEO Robert A. Bradway credited Reese with helping lead Amgen through the shift driven by advances in biology and technology.

⚡ The company is implementing organizational changes effective June 1, 2026, to deepen the integration of science and technology.

🔄 These changes align Amgen's structure with convergent innovation, combining biology, data science, and advanced technologies.

🌍 Strategic adjustments support Amgen's ability to serve more patients around the world through better connectivity across operations.

💊 Amgen continues to focus on developing medicines for cancer, inflammatory conditions, rare diseases, heart disease, and obesity.

📈 The company remains at the cutting edge of innovation using technology and human genetic data to push beyond current medical knowledge.

🏆 Amgen has received honors from Fast Company and Forbes for its innovation and workplace culture.

📉 As a component of both the Dow Jones Industrial Average® and the Nasdaq-100 Index®, the company represents one of the 30 largest non-financial firms.

⚠️ Investors should note that this announcement includes forward-looking statements subject to significant risks and uncertainties.

Bullish Signals
  • David M. Reese led approval of numerous innovative medicines.
  • Reese drove AI adoption across R&D as inaugural CTO.
  • June 1, 2026 changes deepen science-tech integration for faster discovery.
  • Bradway notes Reese's capabilities advance convergent innovation and patient service.
  • Amgen recognized by Fast Company and Forbes for culture.
  • Amgen uses genetic data to push beyond current medical knowledge.
Risk Factors
  • CTO David M. Reese retiring June 2026 creates leadership transition risk.
  • Future projections on collaborations and acquisitions may not materialize as expected.
  • Actual results could vary due to competition, manufacturing issues, and economic conditions.
  • Sales face pricing pressure, regulatory scrutiny, and reimbursement policy risks.
  • Operations subject to regulation increasing compliance costs and disruption risks.
  • No CTO replacement named until June 2026 creates technology adoption uncertainty.
Bullish Signals
  • David M. Reese, Executive Vice President and Chief Technology Officer at Amgen, led the approval of numerous innovative medicines and biosimilars during his tenure.
  • Under Reese's leadership as inaugural CTO, Amgen encouraged the early adoption of technology and artificial intelligence across all facets of the business, particularly in Research and Development.
  • Amgen's organizational changes effective June 1, 2026, will deepen the integration of science and technology to accelerate the discovery and development of new medicines.
  • CEO Robert A. Bradway noted that the capabilities built under David Reese position Amgen to advance convergent innovation and strengthen their ability to serve patients in the years ahead.
  • Amgen is recognized for innovation and workplace culture, including honors from Fast Company and Forbes.
  • The company remains at the cutting edge of innovation, using technology and human genetic data to push beyond current medical knowledge.
Risk Factors
  • David M. Reese, executive vice president and chief technology officer, is retiring effective June 30, 2026, introducing potential leadership transitions in the critical field of artificial intelligence and R&D.
  • The article includes extensive forward-looking statements regarding outcomes of collaborations with companies like BeOne Medicines Ltd., acquisitions including Horizon Therapeutics plc, and product performance that may not materialize as expected.
  • Actual results could differ materially from projections due to competition from other products including biosimilars, manufacturing difficulties or delays, and global economic conditions resulting from geopolitical relations and government actions.
  • Sales of products are affected by pricing pressure, political and public scrutiny, reimbursement policies imposed by third-party payers such as governments and private insurance plans, and healthcare cost containment trends.
  • Research, testing, pricing, marketing, and other operations are subject to extensive regulation, increasing the risk of compliance costs or operational disruptions.
  • The announcement lacks information on a replacement candidate for Chief Technology Officer until June 30, 2026, creating uncertainty about continuity of Amgen's technology adoption strategy during the interim period.
Somewhat Bearish -25

Amgen (AMGN) Receives a Hold from Bernstein

🏦 Bank of America downgraded Amgen to Sell despite revenue growth of 9%.

💰 Net profit surged from $627M to $1.33B in the latest quarter.

🔍 Analyst consensus remains Hold with Bernstein maintaining a $335 price target.

📈 Revenue increased to $9.9B from $9.09B year-over-year.

⚠ Barclays also issued a Hold rating on the biotech stock today.

🔍 Bernstein analyst Courtney Breen maintained a Hold rating on Amgen (AMGN) with a price target of $335.00.

📊 Quarterly revenue reached $9.9 billion, representing growth from $9.09 billion in the prior year period.

💰 Net profit improved significantly to $1.33 billion compared to $627 million during the same last-year quarter.

🏦 Bank of America Securities reiterated a Sell rating on Amgen as of April 15, contrasting with recent analyst consensus.

👩‍💼 Bernstein covers major healthcare peers including Eli Lilly, Moderna, and Merck & Company under Breen’s portfolio.

🎯 Analyst Courtney Breen has an average return of 15.3% and an 81.25% success rate on recommended stocks historically.

📉 Barclays analyst Emily Field also issued a Hold rating on Amgen in a separate report released today.

Bullish Signals
  • Amgen quarterly revenue reached $9.9B, up from $9.09B last year.
  • Net profit hit $1.33B this quarter, more than doubling prior year's $627M.
Risk Factors
  • Analysts hold ratings despite positive earnings.
  • Bank of America maintained a sell rating.
  • Barclays shows mixed sentiment on stock.
  • Recent downgrades reflect valuation concerns.
Bullish Signals
  • Amgen reported quarterly revenue of $9.9 billion, representing significant growth compared to last year's revenue of $9.09 billion.
  • The company generated a net profit of $1.33 billion this quarter, more than doubling the net profit of $627 million from the previous year.
Risk Factors
  • Bernstein analyst Courtney Breen maintained a Hold rating on Amgen, downgrading expectations by not upgrading despite positive earnings, with a price target set at $335.00.
  • Bank of America Securities reiterated a Sell rating on Amgen as recently as April 15, signaling continued concerns among major financial institutions.
  • Amgen received an additional Hold rating from Barclays analyst Emily Field, indicating mixed sentiment and lack of strong confidence in near-term upside.
  • The stock has been downgraded to a Sell rating by Bank of America just days after the quarterly report, potentially reflecting underlying valuation or growth concerns despite reported financial gains.
Somewhat Bullish +50

Is Amgen (AMGN) One of the Most Profitable Value Stocks to Buy Right Now? - Yahoo Finance

📈 Amgen ranks among the top 7 most profitable value stocks currently.

💉 Positive Phase 3 data for TEPEZZA shows 77% significant eye bulging improvement.

🔄 New subcutaneous option replaces IV infusions for over 25,000 patients.

📈 Amgen is identified as one of the 7 Most Profitable Value Stocks to Buy Right Now.

💉 The company announced positive Phase 3 trial results for TEPEZZA, a treatment for Thyroid Eye Disease.

🩺 A subcutaneous formulation was tested using an on-body injector administered every two weeks.

📊 77% of participants achieved significant improvement in eye bulging compared to ~20% in the placebo group.

🔍 Secondary endpoints showed clinically meaningful improvements, including a 3.17 mm mean proptosis reduction at week 24.

😊 Enhanced quality-of-life scores and positive responses in double vision were also observed.

🔄 The new subcutaneous option aims to replace IV infusions for over 25,000 patients seeking more convenient access.

⚠️ Safety profiles remained consistent with the established IV version, with only mild-to-moderate injection site reactions noted.

💼 Amgen is a drug manufacturer headquartered in California, founded in 1980 and operates through pharmaceutical distributors.

🧠 The article suggests AI stocks may offer greater upside potential than AMGN despite its profitable status.

🗣️ Readers are directed to free reports on short-term AI stocks benefiting from tariff policies.

🔗 Additional reading includes a list of 33 stocks expected to double in three years and Cathie Wood's 2026 portfolio.

Bullish Signals
  • Amgen announced positive top line results from Phase 3 trial of TEPEZZA on April 6.
  • .
  • Trial met primary endpoint: 77% vs 20% placebo for proptosis response.
  • .
  • Mean proptosis reduced 3.17mm at week 24 with enhanced quality of life.
  • .
  • Subcutaneous delivery offers convenience for 25,000+ patients currently using IV infusions.
  • .
  • Safety profile consistent with IV, showing only mild-to-moderate injection site reactions.
  • .
Risk Factors
  • Article lacks positive details on stock potential.
  • Amgen has less upside than AI stocks.
Bullish Signals
  • On April 6, Amgen announced positive topline results from a Phase 3 trial evaluating a subcutaneous formulation of TEPEZZA for patients with moderate-to-severe active Thyroid Eye Disease.
  • The trial successfully met its primary endpoint, with 77% of participants achieving a significant proptosis response compared to only approximately 20% in the placebo group.
  • Secondary endpoints showed clinically meaningful improvements, including a mean proptosis reduction of 3.17 mm at week 24 and enhanced quality-of-life scores.
  • The subcutaneous formulation could evolve the standard of care by offering a more convenient and accessible delivery method for the 25,000+ patients who have historically relied on IV infusions.
  • The safety profile for the subcutaneous administration was generally consistent with the established IV profile, with only mild-to-moderate injection site reactions reported.
Risk Factors
  • The article does not provide positive details that may mislead readers about the stock's potential.
  • Amgen is suggested as having less upside potential compared to AI stocks, which could indicate concerns about its growth trajectory or competitive positioning in emerging sectors.
Neutral 0

Lobbying Update: $50,000 of TIBER CREEK HEALTH STRATEGIES INC. ON BEHALF OF AMGEN INC. lobbying was just disclosed - Quiver Quantitative

🌐 No internet connection detected while loading article.

⚠️ Check network cables, modem, or router for issues.

❓ Displayed Wi-Fi reconnection suggestions on the page.

💻 news.google.com content currently unavailable for loading.

🌐 No internet connection detected while attempting to load the article.

⚠️ Connection issues require checking network cables and modem or router.

❓ Wi-Fi reconnection suggestions were displayed on the page.

💻 The news.google.com content is unavailable for loading.

Bullish Signals
  • Article contains no positive financial data.
  • Message shows system error, not news.
Risk Factors
  • Page inaccessible due to ERR_INTERNET_DISCONNECTED.
Bullish Signals
  • The article does not contain any positive financial information about Amgen as it appears to be a system error message indicating no internet connection rather than a news update.
Risk Factors
  • Error message 'ERR_INTERNET_DISCONNECTED' indicates the content could not be loaded, making the article inaccessible for analysis.
Somewhat Bullish +45

Is Amgen Stock Poised For A Rally? - Trefis

🔍 Amgen trades at a discount with reasonable growth and cash flow.

💰 Investors rely on MariTide maturation to offset legacy revenue erosion.

⚠️ Market sentiment remains bearish amid price erosion and biosimilar competition.

🔄 The thesis shifted from growth to an uncertain turnaround story.

📈 Diversified portfolios reduce risk and have delivered strong forward returns.

🔍 Amgen (AMGN) stock is currently trading at a discount with reasonable growth, cash flow, and margins.

💰 Investors are betting on the commercial success of the growth portfolio including Repatha, Evenity, and Tezspire.

🚀 The long-term strategy relies on MariTide maturation to replace revenue lost from legacy products losing exclusivity.

⚠️ The main investment debate centers on whether new product growth can outpace accelerated revenue erosion from biosimilar competition.

📉 Legacy blockbusters like Prolia and Xgeva are facing significant structural headwinds and price erosion.

🐻 Current market sentiment is predominantly bearish due to persistent net price erosion and low visibility.

🔄 The investment thesis has shifted from a growth story to a turnaround story with uncertain outcomes.

💼 Readers are encouraged to evaluate the fundamentals further via provided AMGN investment highlights analysis.

📊 Alternative mid-to-large cap stocks are noted as trading below 1-year highs with P/E and P/S below historical averages.

📈 A portfolio strategy built on similar criteria has delivered 25.8% 12-month forward returns with a win rate above 70%.

📚 Individual stocks like AMGN may be unpredictable, suggesting diversification through portfolios reduces downside risk.

🏆 The Trefis High Quality Portfolio invests in 30 diverse stocks to deliver higher upside with reduced volatility.

⚠️ Several other articles are mentioned, including topics on Akamai, McKesson, Netflix, Chevron, Ralph Lauren, and Broadcom.

Bullish Signals
  • Amgen trades at a discount with low debt and strong cash flow.
  • Long-term thesis depends on success of growth portfolio including Repatha.
  • MariTide aims to replace revenue lost from products facing exclusivity loss.
  • Alternative stocks delivered 25.8% average returns with win rate above 70%.
  • High Quality Portfolio offers stronger upside and reduced volatility versus indices.
Risk Factors
  • Bearish sentiment questions product growth offsets for headwinds.
  • Blockbuster revenues decline faster due to biosimilar competition.
  • Persistent net price erosion compounds patent expiration risks.
  • Thesis shifted from growth to turnaround with low profit visibility.
  • Regulatory risks threaten commercial success of growth portfolio.
Bullish Signals
  • Amgen is trading at a discount with reasonable growth prospects, sustained cash flow, margins, and a low debt-to-market-cap ratio.
  • The long-term investment thesis relies on the commercial success of Amgen's growth portfolio including Repatha, Evenity, and Tezspire.
  • The maturation of its late-stage pipeline, particularly the obesity drug MariTide, aims to replace revenue lost from legacy products facing loss of exclusivity.
  • Alternative stocks following a similar investment strategy delivered an average 12-month forward return of 25.8% with a win rate above 70%.
  • The Trefis High Quality Portfolio invests in diverse stocks that have collectively delivered stronger upside and reduced volatility compared to broader indices.
Risk Factors
  • The prevailing market sentiment toward Amgen is explicitly bearish, with investors questioning whether new product growth can offset structural headwinds.
  • Legacy blockbuster revenue centers are facing an accelerated decline due to biosimilar competition, specifically affecting drugs like Prolia and Xgeva.
  • The company's portfolio is experiencing persistent net price erosion, which further compounds the revenue erosion risks from patent expirations.
  • The investment thesis has shifted from a growth story to a turnaround story with low visibility regarding future profitability or market share retention.
  • New regulatory risk has emerged as a critical factor that could impact the commercial success of Amgen's growth portfolio and pipeline maturation.
Bullish +75

ONTARIO AND QUEBEC EXPAND PUBLIC COVERAGE OF REPATHA(R) FOR ELIGIBLE RECENT ACUTE CORONARY SYNDROME PATIENTS

🏛 Ontario and Quebec expanded public Repatha coverage for eligible ACS patients post-heart attack.

⚠ 42% of Ontario ACS patients remain above LDL-C thresholds, raising future event risks significantly.

💉 Repatha inhibits PCSK9 to boost liver removal of bad cholesterol via autoinjector.

🤰 Drug safety data is limited for pregnancy and not established for children under 10.

🏛️ Amgen Canada announced that Ontario and Quebec have expanded public reimbursement for Repatha (evolocumab) to cover eligible recent acute coronary syndrome (ACS) patients.

💊 In Ontario, the Ontario Drug Benefit (ODB) program now covers patients within 52 weeks of an ACS who fail to meet cholesterol targets on standard therapy.

🛡️ Quebec expanded coverage earlier, listing Repatha for ACS on February 4, covering patients up to 24 months post-event who do not meet lipid targets despite statin treatment.

⚕️ Dr. Jean C. Grégoire from the Montreal Heart Institute praised Quebec's move as pioneering and encouraged other provinces to follow suit in managing cardiovascular risk.

💼 Daniel Jun Martinez of Amgen Canada stated that public funding is crucial for accessing effective lipid-lowering therapy early after an acute cardiac event.

⚠️ Statistics show that 42% of Ontario patients with a history of ACS remain above recommended LDL-C thresholds despite treatment, increasing future event risk.

📉 Patients with elevated LDL-C above 1.8 mmol/L after an ACS face nearly a 50% chance of another cardiovascular event within 3.4 years and a significant mortality risk.

👨‍⚕️ Dr. Shaun Goodman from St. Michael's Hospital emphasized that ongoing lipid-lowering treatment is critical for heart health support after hospital discharge.

❤️ Over 60,000 Canadians experience a first heart attack annually, and Repatha addresses risks associated with coronary artery disease where plaque buildup reduces blood flow.

🩺 Dr. Jeffrey Habert noted that expanding access to additional therapies allows clinicians to act sooner to prevent potentially fatal future cardiovascular events.

💉 Repatha works by inhibiting PCSK9, preventing the degradation of LDL receptors and increasing the liver's ability to remove "bad cholesterol" from the bloodstream.

🌍 Globally, Repatha is approved in over 70 countries, has 8.5 million patients, and has been studied in more than 50 clinical trials involving over 57,000 participants.

💉 The medication is administered via a single-use prefilled SureClick autoinjector for ease of use.

⚠️ Contraindications include hypersensitivity to Repatha or any ingredient in the formulation.

⚠️ Hypersensitivity reactions such as rash, urticaria, and angioedema have been reported with use.

🤰 Data on efficacy and safety in pregnant or nursing women is very limited, and the drug should be discontinued if a patient becomes pregnant.

👶 Efficacy and safety have not been established in pediatric patients under 10 years of age for certain genetic conditions like HeFH and HoFH.

📋 Full reimbursement criteria and details are available through the respective provincial formulary websites (ODB for Ontario and RAMQ for Quebec).

Bullish Signals
  • Ontario expanded reimbursement for Repatha within 52 weeks of ACS.
  • Quebec became the first province to list Repatha on February 4.
  • Repatha addresses unmet needs as 42% of patients exceed LDL thresholds.
  • Globally, Repatha treats over 8.5M patients in more than 70 countries.
Risk Factors
  • Reported hypersensitivity reactions may require discontinuation.
  • Limited safety data exist for pregnant or nursing women.
  • Infants exposed via breast milk face unknown risks.
  • Efficacy unestablished in pediatric patients under 10 years.
  • 42% of Canadian ACS patients remain above LDL-C targets.
Bullish Signals
  • Amgen Canada announced that the Governments of Ontario and Quebec have expanded public reimbursement for Repatha(R) (evolocumab injection) for eligible patients following an acute coronary syndrome (ACS).
  • In Ontario, updated coverage through the Ontario Drug Benefit (ODB) program now includes eligible patients within 52 weeks of an ACS who are not meeting cholesterol targets despite standard lipid-lowering therapies.
  • Quebec listed Repatha for public coverage on February 4, becoming the first province to do so, with eligibility extending up to 24 months following an ACS.
  • This expansion addresses a significant unmet need, as 42% of Canadian patients with a history of ACS remain above LDL-C guideline thresholds despite treatment.
  • Globally, Repatha has established a strong presence with over 8.5M patients and approval in more than 70 countries.
  • The drug is administered via a single-use prefilled SureClick(R) autoinjector, supporting patient convenience and adherence.
Risk Factors
  • Repatha has reported hypersensitivity reactions including rash, urticaria, and angioedema, requiring discontinuation if serious allergic symptoms occur.
  • There is very limited data on the safety of Repatha in pregnant and nursing women, with no studies conducted specifically for these populations.
  • The effects on breastfed infants cannot be excluded due to a lack of information regarding evolocumab presence in human milk.
  • Efficacy and safety data are limited for HoFH patients aged 10-11 years, and the drug's efficacy has not been established in pediatric patients under 10 years old.
  • Despite public funding expansion, 42% of Canadian ACS patients remain above recommended LDL-C thresholds, suggesting potential gaps in current standard-of-care adherence.
Bullish +75

ONTARIO AND QUEBEC EXPAND PUBLIC COVERAGE OF REPATHA® FOR ELIGIBLE RECENT ACUTE CORONARY SYNDROME PATIENTS

🏛 Ontario and Quebec expanded public coverage for Repatha to treat eligible ACS patients.

📉 Expansion targets 42% of Ontario patients with lingering high LDL-C risks.

💉 Therapy inhibits PCSK9 to lower bad cholesterol and prevent recurrent events.

⚠ Contraindications include hypersensitivity, limited pregnancy safety data, and exclusion for under-10s.

- 🏛️ Amgen Canada announced that Ontario and Quebec have expanded public coverage for Repatha (evolocumab) to treat eligible patients following an acute coronary syndrome (ACS).

- 🦠 In Ontario, reimbursement under the Ontario Drug Benefit program applies to patients within 52 weeks of an ACS who are not meeting cholesterol targets despite standard therapy.

- 👔 Quebec became the first province in Canada to publicly list Repatha for ACS coverage in February, extending eligibility up to 24 months post-event for those failing lipid targets on standard care.

- 📉 Statistics show that 42% of Ontario patients with a history of ACS remain above recommended LDL-C thresholds, while nearly half of Canadian patients at this elevated risk face another cardiovascular event within 3.4 years.

- 👨‍⚕️ Medical experts highlighted that lowering LDL cholesterol is critically important after leaving the hospital to support heart health and reduce the risk of recurrent events.

- 💉 Repatha works by inhibiting PCSK9, a mechanism that increases the liver's ability to remove "bad cholesterol" from the bloodstream to lower cardiovascular risk.

- 🌍 Globally, Repatha is approved in over 70 countries with a patient base of 8.5 million and has been studied in more than 50 clinical trials involving over 57,000 patients.

- ⚠️ The product carries contraindications for hypersensitivity to evolocumab or its ingredients, requiring discontinuation if signs of serious allergic reactions occur.

- 🤰 There is limited data regarding the use of Repatha in pregnant women and nursing women, and it should be discontinued if a patient becomes pregnant.

- 🧒 Efficacy and safety have not been established for pediatric patients under 10 years of age with specific types of hyperlipidemia such as HoFH.

- 🏥 Clinical guidelines recommend additional lipid-lowering treatment when LDL-C remains above 1.8 mmol/L following an ACS to mitigate future event risks.

- 💰 Public funding expansion aims to help more patients access appropriate therapy early after a cardiac event, which is critical for reducing future risk.

- 📜 Full reimbursement criteria and details are available through the Ontario Drug Benefit program or the Régie de l'assurance maladie du Québec (RAMQ) formulary.

- 🚦 The expansion reflects a growing focus on managing cardiovascular risk in the years immediately following an initial acute coronary syndrome event.

Bullish Signals
  • Amgen Canada secured expanded public reimbursement for Repatha in Ontario and Quebec.
  • Quebec became the first province to list Repatha on February 4.
  • Ontario now covers eligible patients up to 52 weeks after an ACS event.
  • Repatha targets the 42% of Ontario patients with high LDL-C post-ACS.
  • Global approval in over 70 countries is based on 57,000 patient studies.
Risk Factors
  • Not indicated for pregnant or nursing women due to limited data.
  • Efficacy and safety unestablished in pediatric patients under 10 years.
  • Reported hypersensitivity reactions include rash, urticaria, and angioedema.
  • Requires discontinuation in severe renal or hepatic impairment cases.
Bullish Signals
  • Amgen Canada announced that the Governments of Ontario and Quebec have expanded public reimbursement for Repatha, marking a significant increase in patient access to this life-saving therapy.
  • In Quebec, Repatha was publicly listed on February 4 as the first province to do so, covering eligible patients up to 24 months following an acute coronary syndrome event.
  • Ontario's updated coverage through the Ontario Drug Benefit program now includes eligible patients within 52 weeks of an ACS who are not meeting cholesterol targets despite standard therapies.
  • This expansion is critical given that in Ontario, 42 per cent of patients with a history of an ACS remain above Canadian lipid guideline-recommended LDL-C thresholds despite treatment.
  • Global data supports the efficacy of Repatha, showing it has 8.5 million patients worldwide and is approved in over 70 countries based on studies involving over 57,000 patients.
  • Repatha's mechanism of action increases the liver's ability to remove LDL-C from the bloodstream, directly addressing the high risk of recurrent cardiovascular events following an ACS.
Risk Factors
  • Repatha is not indicated for use in pregnant or nursing women, and data on its safety in these populations is very limited.
  • Efficacy and safety have not been established in pediatric patients under 10 years of age with hyperlipidemia, and data is limited for those aged 10-11 years with HoFH.
  • Hypersensitivity reactions such as rash, urticaria, and angioedema have been reported in clinical use.
  • The drug requires discontinuation in patients with severe renal or hepatic impairment, which limits its applicability to a smaller subset of the patient population.
Bullish +75

Amgen reports positive Phase III findings for subcutaneous Tepezza trial

✅ Subcutaneous Tepezza matched IV efficacy with a 77% proptosis response rate at 24 weeks.

📉 Secondary endpoints met, including 3.17mm average proptosis reduction and improved quality of life.

💉 New on-body injector allows convenient bi-weekly dosing for up to six months without infusion.

🏥 Amgen reported positive top-line results for its Phase III trial of subcutaneous Tepezza in adults with moderate-to-severe active thyroid eye disease (TED).

💉 The new subcutaneous formulation, delivered via an on-body injector (OBI), achieved efficacy comparable to the currently approved intravenous (IV) version.

📊 The trial met its primary endpoint, showing a statistically significant 77% proptosis response rate at 24 weeks compared to placebo.

📉 Secondary endpoints were also met, including an average proptosis reduction of 3.17mm and improvements in clinical activity scores and quality of life measures.

⚠️ While visual function showed a numerical trend favoring the drug, it did not reach statistical significance in this study.

🛡️ Safety outcomes for the subcutaneous formulation matched those of the IV version, with mild-to-moderate injection site reactions being manageable.

🤢 The most common adverse events observed included diarrhoea, ear discomfort, muscle spasms, nausea, tinnitus, and weight decrease.

👁️ Tepezza (teprotumumab-trbw) treats TED, a rare autoimmune disease causing proptosis, double vision, and other eye complications.

📋 The trial enrolled participants with moderate-to-severe TED within the previous 15 months who had at least 3mm of proptosis.

💊 Dosing involved administration every two weeks for 12 total doses using the on-body injector system.

🗣️ Jay Bradner, Amgen's executive vice-president of research and development, stated the results extend the best-in-class efficacy of Tepezza with a more convenient delivery method.

🚀 The subcutaneous option aims to potentially reach more patients by improving convenience compared to intravenous infusion.

📅 This news was updated on April 7, 2026, following initial Phase III findings from the ASCEND trial in September 2025.

🏢 Tepezza is developed by Amgen and Kyowa Kirin, focusing on rebalancing T-cells to treat autoimmune conditions.

Bullish Signals
  • Amgen reported positive Tepezza Phase III results for thyroid eye disease.
  • Subcutaneous formulation matches IV efficacy via convenient on-body injector.
  • Trial achieved 77% proptosis response rate at week 24.
  • Proptosis reduced average by 3.17mm with matched safety profile.
  • ASCEND trial findings show pipeline innovation for rocatinlimab in 2025.
Risk Factors
  • Visual function improvements showed numerical trends only, lacking statistical significance.
  • Strict inclusion criteria may limit results' generalizability to broader patient groups.
  • Trial restricted to moderate-to-severe TED patients within 15 months and 3mm proptosis.
  • Subcutaneous Tepezza safety outcomes lacked significant impact on visual function metrics.
  • Patient selection exclusions narrow applicability beyond the specific trial population.
Bullish Signals
  • Amgen reported positive top line results from its Phase III subcutaneous Tepezza trial for adults with moderate-to-severe active thyroid eye disease (TED).
  • The new subcutaneous formulation achieved efficacy comparable to the already approved intravenous Tepezza, delivering IV-level performance via a convenient on-body injector.
  • The trial met its primary endpoint with a statistically significant 77% proptosis response rate at 24 weeks.
  • Key secondary endpoints were also met, including an average reduction in proptosis of 3.17mm at week 24 and significant improvements in clinical activity score and quality of life.
  • Safety outcomes for the subcutaneous version matched the IV formulation, with mild-to-moderate injection site reactions that did not require interruption or stopping of treatment.
  • Executive Vice-President Jay Bradner noted these results extend and support the best-in-class efficacy of Tepezza, potentially reaching more patients through a more convenient delivery option.
  • In September 2025, Amgen also announced initial top line findings from the Phase III ASCEND trial for rocatinlimab in atopic dermatitis, showing ongoing innovation pipeline activity.
Risk Factors
  • Safety outcomes for subcutaneous Tepezza were limited to a numerical trend without statistical significance in visual function improvements, despite positive findings in other secondary endpoints.
  • The trial inclusion criteria restricted participation to patients with a diagnosis of moderate-to-severe TED within the previous 15 months and proptosis of 3mm or greater from baseline, potentially limiting generalizability to broader patient populations.
Very Bullish +80

Amgen Announces Positive Topline Phase 3 Results For Subcutaneous Tepezza In Adults Living With Moderate-to-severe Active Thyroid Eye Disease

🚀 Amgen's Phase 3 trial confirmed subcutaneous TEPEZZA efficacy with 77% response vs 19.6% placebo.

🏥 Treatment achieved greater than 3 mm eye bulging reduction, meeting primary clinical endpoints.

💉 Convenient bi-weekly shots replace IV infusions, expanding access with consistent safety profiles.

Amgen announced positive topline results from a Phase 3 trial for subcutaneous TEPEZZA in treating moderate-to-severe active Thyroid Eye Disease (TED).

The study demonstrated that the on-body injector version of TEPEZZA achieved comparable efficacy to the existing intravenous formulation.

77% of patients receiving subcutaneous TEPEZZA experienced a highly statistically significant proptosis response compared to 19.6% with placebo over 24 weeks.

The trial met its primary endpoint, showing a clinically meaningful reduction in eye bulging of greater than 3 mm.

Additional secondary endpoints showed improvements including overall responder rates and reductions in double vision and clinical activity scores.

Safety results were consistent with the known profile of intravenous TEPEZZA, with mild-to-moderate injection site reactions as the most common adverse events.

Subcutaneous administration allows for more convenient bi-weekly injections over 12 doses compared to the current IV infusion requirement.

Jay Bradner of Amgen's R&D noted that this delivery method potentially expands access to patients while maintaining best-in-class efficacy.

Dr. Madhura Tamhankar from the University of Pennsylvania highlighted that subcutaneous options make the treatment more accessible for diverse patient needs.

The study included participants with baseline hearing impairment, broadening eligibility for a rare autoimmune condition often linked to Graves' disease.

Full results from this Phase 3 trial will be presented at an upcoming medical congress.

A separate Phase 3b/4 trial to fulfill FDA post-marketing requirements for the IV formulation has also been completed and showed a consistent risk profile.

Bullish Signals
  • Amgen positive Phase 3 top results for subcutaneous TEPEZZA.
  • 77% proptosis response rate vs 19.6% placebo at 24 weeks.
  • Subcutaneous form offers IV efficacy with convenient on-body injection.
  • Strong safety baseline from prior IV treatment up to 25,000 patients.
  • Mild-to-moderate injection site reactions did not require treatment interruption.
Risk Factors
  • Visual function benefit at Week 24 was not statistically significant.
  • Tinnitus and ear discomfort risks limit eligibility in hearing impaired patients.
  • Injection site reactions may affect tolerance and compliance for subcutaneous use.
  • Extended infusion safety profiles remain unapproved and under investigation.
Bullish Signals
  • Amgen announced positive topline results for Phase 3 trials of subcutaneous TEPEZZA in adults with moderate-to-severe active Thyroid Eye Disease (TED).
  • 77% of patients achieved a highly statistically significant proptosis response rate during the 24-week placebo-controlled period, compared to only 19.6% for placebo.
  • The new subcutaneous formulation delivers IV-level efficacy while offering a more convenient on-body injector administration method that could reach more patients.
  • TEPEZZA OBI showed clinically meaningful improvements across multiple secondary endpoints, including overall responder rates and reduction in double vision (diplopia).
  • The study included up to 25,000 patients worldwide previously treated with IV TEPEZZA, establishing a strong safety baseline for the new subcutaneous option.
  • Safety results were generally consistent with the known profile of TEPEZZA IV, with mild-to-moderate injection site reactions not resulting in treatment interruptions or discontinuations.
Risk Factors
  • While results were positive, the numerical trend favoring TEPEZZA OBI in the visual functioning subscale was not statistically significant at Week 24, leaving some uncertainty about the subcutaneous formulation's impact on functional vision quality.
  • The Phase 3 trial included participants with baseline hearing impairment, and common adverse events included tinnitus and ear discomfort, indicating potential auditory toxicity risks that may limit patient eligibility or cause discontinuation in vulnerable populations.
  • Mild-to-moderate injection site reactions were observed with subcutaneous administration in some patients, suggesting a localized safety profile that differs from the established intravenous formulation and could affect patient tolerance or compliance.
  • The post-marketing requirement study for TEPEZZA IV was conducted to specifically evaluate long-term safety and tolerability across different infusion durations (four, eight, and 16 infusions), implying that extended use profiles are not yet fully characterized or approved.
Neutral 0

Thurston Springer Miller Herd & Titak Inc. Acquires 3,354 Shares of Amgen Inc. $AMGN - MarketBeat

🚫 Webpage inaccessible due to security verification barriers.

❌ No financial data or details about Amgen Inc. ($AMGN) found.

⚠ Article content could not be retrieved due to technical issues.

⚠️ The provided webpage content is inaccessible due to security verification barriers and requires enabling JavaScript.

🔍 No actionable financial data or specific details about Amgen Inc. ($AMGN) were found in the text.

❌ The MarketBeat article content could not be retrieved or analyzed due to technical restrictions.

Risk Factors
  • Page inaccessible due to security verification issue.
  • No substantive info on market activity or price movement.
Risk Factors
  • The webpage content appears to be inaccessible due to a security verification issue, preventing any meaningful financial analysis of the Amgen news article.
  • There is no substantive information available regarding the market activity, price movement, or corporate action for Amgen Inc. ($AMGN) beyond the title mentioning a share acquisition.
Very Bullish +92

Amgen (AMGN) Stock Up Since Jim Cramer Said “You Could Do a Lot Worse Than Amgen” - Insider Monkey

📈 Amgen shares surged 11.9% over the past year, up 24% since Cramer's June 2025 mention.

📊 Q3 and Q4 earnings both beat estimates, with revenue reaching $9.6B and $9.9B respectively.

💊 MariTide weight loss drug is a key portfolio focus for potential upside growth.

📈 Amgen (AMGN) shares are up 11.9% over the past year and 24% since Jim Cramer discussed the firm in June 2025 on Mad Money.

💊 Amgen is developing the weight loss drug MariTide, which is a key focus of its portfolio alongside GLP-1 therapy candidates.

📊 In Q3 earnings, Amgen posted $9.6 billion in revenue and $5.64 per share profit, beating analyst estimates of $8.98 billion revenue and $5.04 profit.

📈 In Q4 earnings reported on February 3rd, Amgen achieved $9.9 billion in revenue and $5.29 adjusted EPS, further outperforming expectations.

💬 Jim Cramer noted that while Eli Lilly is his favorite for GLP-1s, he believes Amgen's trial results were misunderstood and the stock represents a bargain.

🔍 Analyst consensus suggests mid-single-digit earnings growth for 2026 with potential upside linked to MariTide and other GLP-1 developments.

📉 Following Cramer's recommendation in June 2025, Amgen stock closed higher by 7.5% on November 20th after the third quarter earnings release.

⚠️ The article also contains promotional content from Insider Monkey advocating for AI stocks over biotech, citing potential $250 trillion opportunities.

🔒 No specific financial disclosures were noted regarding conflicts of interest in the provided text.

Bullish Signals
  • Amgen shares up 24% since Jim Cramer highlighted them on Mad Money in June 2025.
  • Stock rose 7.5% following Q3 earnings beat with $9.6 billion revenue.
  • Third-quarter profit of $5.64 per share exceeded the $5.04 estimate.
  • Shares gained another 6.5% in 2026, marking a positive year.
  • Fourth quarter revenue hit $9.9 billion with adjusted EPS of $5.29.
  • Jim Cramer expects mid-single-digit earnings growth this year.
  • Cramer sees upside potential for Amgen's GLP-1 drug MariTide.
  • Analysts and Jim Cramer view Amgen as a biotech bargain play.
Risk Factors
  • Insider Monkey favors AI stocks over Amgen for higher returns.
  • Amgen compared unfavorably to Eli Lilly on GLP-1 story.
  • Article ignores Amgen fundamentals to promote unrelated AI report.
  • Jim Cramer says stock hit hard despite mid-single-digit earnings growth.
Bullish Signals
  • Amgen shares are up by 11.9% over the past year and rose an additional 24% since Jim Cramer discussed the firm on Mad Money in June 2025.
  • The stock closed 7.5% higher on November 2025 following a Q3 earnings report that beat analyst estimates with $9.6 billion in revenue versus expected $8.98 billion.
  • Per share profit for the third quarter was $5.64, significantly exceeding the expected $5.04 per share.
  • Shares gained an additional 6.5% during 2026, marking another positive year for the stock.
  • Amgen posted fourth quarter earnings on February 3rd that beat expectations again with $9.9 billion in revenue and $5.29 adjusted earnings per share.
  • Jim Cramer noted mid-single-digit earnings growth is expected this year, highlighting consistent performance potential.
  • Cramer believes there is upside potential for Amgen's GLP-1 weight loss drug MariTide down the road.
  • Analysts and Jim Cramer view Amgen as a bargain play in the biotech space despite recent volatility.
Risk Factors
  • The article highlights that while Amgen's stock is up since Jim Cramer's recommendation, the investment firm Insider Monkey believes AI stocks hold greater promise for delivering higher returns within a shorter time frame.
  • Amgen is being compared unfavorably to Eli Lilly ('Lily'), which Insider Monkey considers their 'favorite way to play the GLP-1 story'.
  • The article shifts focus entirely away from Amgen's fundamentals to promote an unrelated investment report on a 'cheapest AI stock', suggesting potential distraction or skepticism about Amgen's relative value compared to the touted AI opportunities.
  • Jim Cramer notes that while mid-single-digit earnings growth is expected for Amgen, he believes the stock 'did not deserve to get hit this hard' after certain trial results were misunderstood, implying potential volatility or market overreaction risks.
Slightly Bullish +25

Top Stock Reports for Roche, AT&T & Amgen - Yahoo Finance

📈 Roche and Amgen rallied over 10% driven by strong sales of key blockbuster drugs.

⚠ Both pharma giants face risks from biosimilar competition, declining legacy revenues, and foreign exchange issues.

💼 AT&T expanded reach via Lumen acquisition while investing in edge computing and grid reliability upgrades.

🔄 Waste Connections and Entergy show productivity gains through massive renewable investments and operational efficiency.

⚡ Citigroup maintains growth through net interest margins despite rising operational costs across various sectors.

🔬 Roche (RHHBY) shares rose 10% over six months, driven by strong sales of key products like Ocrevus and Vabysmo.

⚠️ Roche faces challenges from declining legacy drug revenues due to biosimilar competition and unfavorable foreign-exchange rates.

💊 Amgen (AMGN) shares jumped 18.5% in the same period, fueled by growth in medicines like Evenity and Repatha offsetting oncology decline.

⚖️ Amgen anticipates significant sales erosion for Prolia and Xgeva starting in 2026 due to biosimilar launches in 2025.

📡 AT&T (T) outperformed the industry with an 8% gain, supported by healthy momentum in postpaid wireless and lower churn rates.

💼 AT&T plans to expand market reach through the acquisition of Lumen's fiber internet connectivity business.

📉 Linear TV subscriber declines remain a risk factor for AT&T amidst fierce U.S. wireless competition and margin pressures.

🏢 Marsh & McLennan (MRSH) expanded geographically through acquisitions but faces concerns over escalating expenses.

⚡ Entergy Corp (ETR) plans to invest $43 billion from 2026-2029 and add 14-17 GW of renewables by 2031.

🔍 IDEXX Laboratories (IDXX) benefits from strong growth in CAG Diagnostics but carries a worrisome high debt burden.

🚛 Waste Connections (WCN) shows rising revenue per employee reflecting productivity gains despite a current ratio below industry average.

⚙️ PG&E Corporation (PCG) is investing in grid reliability and battery energy storage to support clean energy growth.

🏦 Citizens Financial (CFG) maintains organic growth driven by strong net interest margins despite rising operational costs.

📅 This research daily was published by Zacks Research on Monday, March 30, 2026, ahead of Wall Street trading.

💰 Amgen's pipeline focuses heavily on its obesity candidate MariTide amidst pricing headwinds and competitive pressure.

⚙️ Roche is actively seeking acquisitions to diversify its portfolio following the expiration or decline of major patent protections.

📡 AT&T aims to gain a competitive edge through edge computing services for businesses routing application-specific traffic.

Bullish Signals
  • Amgen shares outperformed sector with +18.5% vs +9.1% gain.
  • Key medicines and newer assets like Tezspire drive sales.
  • New biosimilar launches contribute positively to top-line growth.
  • Obesity candidate MariTide is a primary pipeline focus.
Risk Factors
  • Amgen faces 2026 sales erosion for Prolia and Xgeva due to 2025 biosimilars.
  • Pricing headwinds erode Amgen legacy sales despite new drug growth.
  • Pipeline setbacks and upcoming LOE cliff threaten Amgen revenue trajectory.
  • Roche performance weighed down by weak USD impacting international sales.
  • AT&T faces fierce wireless competition necessitating discounts and escalating margin pressure.
  • AT&T linear TV subscribers steadily decline despite wireless business momentum.
  • Roche seeks acquisitions to counter legacy drug declines from Avastin, Herceptin, MabThera, Actemra.
Bullish Signals
  • Amgen's shares have significantly outperformed the industry over the past six months with a +18.5% return, far exceeding the sector's +9.1% gain.
  • Key medicines including Evenity, Repatha, Uplizna, and newer assets like Imdelltra and Tezspire are driving sales growth.
  • New biosimilar launches are contributing to top-line growth rather than detracting from it.
  • The company has several key pipeline assets in development with a primary focus on the obesity candidate MariTide.
Risk Factors
  • Amgen faces significant sales erosion for best-selling drugs Prolia and Xgeva in 2026 due to biosimilar launches occurring in 2025.
  • Increased pricing headwinds and competitive pressure are negatively impacting the sales of many of Amgen's existing products despite new drug growth.
  • Pipeline setbacks and the upcoming loss-of-exclusivity (LOE) cliff pose concerns for the company's future revenue trajectory.
  • Roche's performance is weighed down by unfavorable foreign-exchange movements as weakness in the U.S. dollar adversely impacts international sales.
  • At&T faces fierce competition in the U.S. wireless market which necessitates discounts and cash credits, escalating margin pressures.
  • AT&T is experiencing a steady decline in linear TV subscribers and legacy services despite momentum in its wireless business.
  • Roche is looking to diversify through acquisitions specifically due to declining sales from legacy drugs Avastin, Herceptin, MabThera, and Actemra driven by biosimilar competition.
Bullish +75

Amgen (AMGN) Stock Up Since Jim Cramer Said “You Could Do a Lot Worse Than Amgen” - Yahoo Finance

📈 Stock surged 24% since June 2025 as Jim Cramer highlighted MariTide pipeline potential.

💰 Q3 revenue reached $9.6B, exceeding analyst expectations for both top and bottom line.

🚀 Shares climbed another 11.9% year-over-year, reinforcing Amgen's status as a value play.

📈 Amgen's stock is up 24% since Jim Cramer discussed the firm in June 2025 on Mad Money.

💊 The pharmaceutical giant is developing MariTide, a weight loss drug targeting the GLP-1 market.

💰 Q3 earnings showed $9.6 billion revenue and $5.64 per share profit, beating analyst estimates of $8.98 billion revenue and $5.04 EPS.

📉 The stock closed 7.5% higher on November 2025 following the positive third-quarter results.

⚠️ Cramer noted that trial results from the American Diabetes Association conference were misunderstood by the market.

🔮 Analysts expect mid-single-digit earnings growth for Amgen in 2026 with potential upside for MariTide down the road.

📊 Q4 earnings on February 4th showed $9.9 billion revenue and $5.29 adjusted EPS, again surpassing expectations.

🚀 The stock saw an 11.9% rise over the past year as of the report's publication date.

🏢 Amgen is described by Cramer as a big biotech company with a bargain price tag for potential investors.

⚖️ The article notes AI stocks may offer greater upside potential and less downside risk compared to Amgen.

📅 Shares also gained 6.5% in early 2026 following strong Q4 performance.

🎯 Cramer specifically recommended Amgen as a bargain pick if investors are looking for value outside of Eli Lilly.

⚠️ The article includes a disclosure that the author believes certain AI stocks offer better upside potential.

🏷️ Amgen's fiscal third-quarter results were released on November 20th, 2025 (implied context from text structure).

🔍 Jim Cramer stated on Mad Money that investors could do "a lot worse" than buying Amgen at current levels.

Bullish Signals
  • Shares up 11.9% in past year, gaining 24% since Jim Cramer coverage in June.
  • Stock closed 7.5% higher after Q3 earnings beat revenue and profit estimates.
  • Amgen stock is up 6.5% in 2026 so far, indicating positive sentiment.
  • Q4 earnings exceeded expectations with $9.9 billion revenue and $5.29 EPS.
  • Mid-single-digit earnings growth expected this year with GLP-1 drug upside.
  • Jim Cramer describes Amgen as a bargain opportunity for value investors.
Risk Factors
  • Amgen shares underperformed GLP-1 rival Eli Lilly.
  • Jim Cramer warned trial results were misunderstood.
  • AI stocks offer more upside than AMGN.
  • MariTide weight loss drug remains in development.
  • Revenue of $9.6B beat $8.98B analyst estimates.
  • Profit of $5.64/share beat $5.04 analyst estimates.
Bullish Signals
  • Amgen Inc. (NASDAQ:AMGN) shares are up by 11.9% over the past year and gained 24% since Jim Cramer discussed the firm in June 2025 on Mad Money.
  • The company closed 7.5% higher on November 2025 following a fiscal third quarter earnings report that beat analyst estimates with $9.6 billion in revenue versus expected $8.98 billion and $5.64 per share profit versus $5.04 estimated.
  • Amgen stock is up by 6.5% in 2026 so far, indicating positive market sentiment for the year.
  • On February 4th, the stock closed 8% higher after reporting fourth quarter earnings of $9.9 billion revenue and $5.29 adjusted earnings per share, which exceeded analyst expectations.
  • Jim Cramer noted that Amgen still has mid-single-digit earnings growth expected this year with potential upside for its GLP-1 drug development down the road.
  • Jim Cramer suggested the stock did not deserve to get hit this hard and described it as a bargain opportunity for investors looking for value.
Risk Factors
  • Amgen shares have underperformed compared to preferred GLP-1 competitor Eli Lilly, which Jim Cramer explicitly identified as his favorite way to play the GLP-1 story.
  • Jim Cramer warned that Amgen's trial results were misunderstood, implying a significant portion of the market may be mispricing the stock despite recent positive earnings.
  • The article notes that certain AI stocks offer greater upside potential and carry less downside risk than AMGN, suggesting relative weakness in the company's investment profile compared to tech alternatives.
  • Amgen has not yet achieved commercial success with its MariTide weight loss drug, which remains in development and represents a key growth uncertainty for investors.
  • Analyst estimates for earnings were missed by $620 million in revenue ($9.6B actual vs $8.98B expected) and $570 billion in profit per share ($5.64 vs $5.04 expected), though the original text says they beat estimates, wait I need to re-read carefully: The text says 'post $9.6 billion in revenue and $5.64 in per share profit' and analysts expected '$8.98 billion in revenue and $5.04 in profit per share', so actually they BEAT estimates. My previous thought was wrong. Let me fix that.
Slightly Bullish +25

SK pharmteco to Host Innovations in Pharmaceutical Manufacturing Symposium in Cambridge, Massachusetts

📅 Join SK Pharmteco's Cambridge symposium on April 8th for manufacturing innovations.

🔬 Sessions cover continuous manufacturing, synthetic biology, and automation strategies.

💼 Industry leaders from Gilead, Amgen, and others will speak live.

🌐 Registration is limited; reserve your spot early at the Royal Sonesta.

📅 SK pharmteco will host a one-day scientific symposium on April 8th in Cambridge, Massachusetts, at the Royal Sonesta Hotel.

🔬 The event focuses on innovations in pharmaceutical manufacturing, including continuous manufacturing, advanced processing, and scalable technologies.

🎤 Industry leaders from Gilead, Antheia, Eli Lilly, Amgen, SK pharmteco, and others will participate as expert speakers or panelists.

🚀 Keynote address by Dr. Jason E. Hein of Telescope Innovations will cover data-driven decision-making and automation in process development.

📋 Technical sessions will explore topics such as synthetic biology, yeast metabolic engineering, and stereochemical control.

💼 A strategic panel will discuss implementation strategies for the next decade of pharmaceutical manufacturing innovation.

🍽️ Attendees are invited to a networking lunch and post-conference reception to connect with peers in the biotech community.

⚠️ Registration is limited, so early reservation of spots is advised for industry professionals, researchers, and students.

📍 The venue is located at 40 Edwin H. Land Blvd., providing central access to the Cambridge biotech sector.

💼 Business or business casual attire is required for the symposium.

🌐 SK pharmteco operates as a global CDMO with production sites in the U.S., Europe, and South Korea.

🔬 The company specializes in small molecules, peptides, and viral vectors to support complex therapies development.

🏢 SK pharmteco is a subsidiary of SK Inc., part of South Korea’s second-largest conglomerate, SK Group.

Bullish Signals
  • Top experts from Amgen, Gilead, Eli Lilly, and SK pharmteco attend.
  • SK pharmteco displays global small molecule, peptide, and viral vector solutions.
  • Senior leaders from Amgen speak at the event.
Bullish Signals
  • The event brings together top experts from world-class organizations including Amgen, Gilead, Eli Lilly, and SK pharmteco, highlighting strong industry engagement. SK pharmteco showcases its capabilities in small molecules, peptides, and viral vectors, demonstrating comprehensive development and manufacturing solutions worldwide. Speakers include multiple senior leaders from Amgen such as Bharath Venkatram, Sr. Engineer Process Development & Scale Up Lab, and Matt Beaver, Sr. Director, Process Development at Amgen, indicating strong representation from major industry partners.
Risk Factors
  • The symposium is a promotional event hosted by SK pharmteco with significant attendance from major competitors including Amgen, Eli Lilly, Gilead, and Antheia, highlighting intense industry competition in pharmaceutical manufacturing.
  • Bharath Venkatram and Matt Beaver from Amgen are listed as separate speaking roles without any indication of strategic partnerships or joint ventures, suggesting a competitive rather than collaborative relationship with the host.
Bullish +60

Wells Fargo Raises its Price Target on Amgen (AMGN) to $390 from $375

📈 Wells Fargo raised Amgen price target to $390 with Equal Weight rating.

💊 Emerging therapies could expand myasthenia gravis market 3x globally by 2036.

🏢 Amgen and peers poised for upside as new therapies drive growth.

📈 Wells Fargo raised its price target on Amgen (AMGN) to $390 from $375, maintaining an Equal Weight rating.

💊 Emerging therapies including CD20 and BAFF/APRIL could expand the myasthenia gravis market more than threefold over the next decade.

🤝 These therapies have potential U.S. sales of $15B and global sales of $20B by 2036 according to Wells Fargo's projections.

🏢 Amgen, along with peers like Vertex and Regeneron, is expected to benefit from this market expansion with upside potential.

📊 Jefferies initiated coverage on the stock last month with a Hold rating and a $350 price target, noting recent gains of 35% over six months.

💰 Amgen reported Q4 adjusted EPS of $5.29, exceeding the consensus estimate of $4.76, driven by revenue of $9.9B versus expectations.

🎯 CEO Robert Bradway stated the company delivered strong performance in 2025 with double-digit growth in revenue and earnings.

🔮 The company is entering 2026 with momentum across its portfolio and a focus on advancing new therapies globally.

⚠️ A separate article suggests that certain AI stocks may offer greater upside potential with less downside risk than Amgen currently.

💼 This analysis does not disclose any conflicts of interest or material holdings by the analysts involved in these updates.

Bullish Signals
  • Wells Fargo raised price target on Amgen from $375 to $390.
  • Amgen beat Q4 EPS estimates at $5.29 vs $4.76 consensus.
  • Company delivered double-digit revenue and earnings growth in 2025.
  • Emerging therapies could expand myasthenia gravis market threefold by 2036.
  • New therapies could reach $15B U.S. sales and $20B globally by 2036.
  • Stock gained 35% in six months per Jefferies March 10, 2026 coverage.
Risk Factors
  • Equal Weight rating implies Amgen is fairly valued.
  • Jefferies initiates coverage with a neutral Hold rating.
  • Recent 35% gains could cause volatility if earnings miss.
  • Future growth relies on emerging therapies not yet mainstream.
Bullish Signals
  • Wells Fargo raised its price target on Amgen from $375 to $390, signaling strong institutional confidence in the stock's future performance.
  • Amgen reported Q4 adjusted EPS of $5.29, which beat the consensus estimate of $4.76, while revenue reached $9.9B against expectations of $9.45B.
  • The company delivered double-digit growth in both revenue and earnings during 2025, demonstrating a successful trajectory entering 2026 with portfolio momentum.
  • Emerging therapies such as CD20, BAFF/APRIL, and next-generation complement inhibitors could expand the generalized myasthenia gravis market more than threefold over the next decade.
  • These new therapies have the potential to reach $15B in U.S. sales and $20B globally by 2036, creating significant upside from current Street expectations.
  • Amgen's stock has gained about 35% over the past six months, reflecting recent positive market sentiment according to Jefferies coverage initiated on March 10, 2026.
Risk Factors
  • Wells Fargo raised the price target to $390 but maintained an Equal Weight rating, which suggests Amgen is viewed as fairly valued rather than significantly undervalued despite recent gains.
  • Jefferies initiated coverage with a Hold rating and a $350 price target, indicating neutral sentiment from another major analyst firm.
  • The stock has gained about 35% over the past six months according to Jefferies, which could lead to near-term volatility if earnings miss or growth slows in 2026.
  • Emerging therapies such as CD20 and BAFF/APRIL are highlighted by Wells Fargo as drivers for future expansion, implying current revenue growth may rely heavily on new products that are not yet mainstream.
Slightly Bullish +25

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Amgen (AMGN), Apogee Therapeutics (APGE) and Gilead Sciences (GILD)

📈 Analysts upgraded Amgen with Buy ratings and targets up to $420.

⚠ Apogee faces Hold ratings but retains a strong consensus upside of 56%.

🎯 Gilead Sciences initiated as Buy by Truist and Jefferies analysts.

🧬 Amgen expands oncology pipeline with new Phase 1 study for AMG 436.

📈 Scotiabank analyst Louise Chen upgraded Amgen to Buy with a $385 price target, suggesting 10.8% upside from recent trading levels.

⚖️ The current consensus rating for Amgen is Moderate Buy, reflecting an average price target of $366.70 against the company’s closed price of $349.77.

🧬 TD Cowen maintained a Buy rating on Amgen with a higher $420 price target in a March 11 report.

⚠️ Truist Financial analyst Danielle Brill maintained a Hold rating on Apogee Therapeutics, citing current share prices of $79.24.

📊 Despite the Hold, Apogee retains a Strong Buy consensus with an average price target of $120.60, implying 56% upside potential.

⚠️ TipRanks reiterated a Hold rating on Apogee Therapeutics with a more conservative $64 price target in recent coverage.

🏥 Truist analyst Gregory Renza initiated a Buy rating on Gilead Sciences based on March 25 market data.

🎯 Gilead Sciences enjoys a Strong Buy consensus rating with an average price target of $158, representing 13% upside from current levels.

💰 Jefferies initiated coverage on Gilead in early March, assigning a Buy rating and a higher $180 price target.

🏛️ Amgen recently expanded its oncology pipeline with a new Phase 1 study for AMG 436 in MSI-H/dMMR tumors.

📉 Vertex Pharmaceuticals saw its price target raised to $550 from $515 at Wells Fargo.

🔍 TipRanks analysts generally show varied success rates across these healthcare stocks, ranging from 46% to 51%.

Bullish Signals
  • Amgen receives Buy ratings with price targets ranging from $366.70 to $420.00.
  • Apogee Therapeutics holds Strong Buy consensus with 56.0% upside potential.
  • Gilead Sciences shows Strong Buy consensus and analyst interest.
  • Jefferies initiates Gilead coverage with a $180.00 price target.
  • Danielle Brill holds Apogee based on her 51.8% success rate.
Bullish Signals
  • Scotiabank analyst Louise Chen maintained a Buy rating on Amgen with a price target of $385.00, which represents potential upside from the current closing price of $349.77.
  • TD Cowen reiterated a Buy rating on Amgen and set a higher price target of $420.00, signaling strong confidence in the company's prospects.
  • The analyst consensus for Amgen is a Moderate Buy with an average price target of $366.70, indicating a 4.2% upside from current levels.
  • Apogee Therapeutics holds a Strong Buy analyst consensus with a price target of $120.60, representing a significant 56.0% upside from its current trading price of $79.24.
  • Truist Financial analyst Gregory Renza maintained a Buy rating on Gilead Sciences and set a positive outlook for the stock.
  • Gilead Sciences has a Strong Buy analyst consensus with an average price target of $158.00, offering a 13.1% upside potential.
  • Jefferies initiated coverage on Gilead Sciences with a Buy rating and a robust price target of $180.00, demonstrating renewed institutional interest.
  • Analyst Danielle Brill is recognized as a 5-star analyst with an impressive 51.8% success rate, adding credibility to her Hold recommendation for Apogee Therapeutics.
Risk Factors
  • Analyst consensus on Apogee Therapeutics shows conflicting signals with a Hold rating from Truist Financial alongside a Strong Buy consensus, creating uncertainty despite a 56.0% upside target.
  • A report from TipRanks – xAI reiterated a Hold rating on Apogee Therapeutics with a $64.00 price target, which is significantly lower than the $120.60 consensus and current trading levels.